Safety, tolerability and pharmacokinetics of liposomal curcumin in healthy humans

International Journal of Clinical Pharmacology and Therapeutics

Volumn 53, Issue 1, 2015, Pages 54-65

  Storka, Angela ^a   Vcelar, Brigitta ^b   Klickovic, Uros ^a   Gouya, Ghazaleh ^a   Weisshaar, Stefan ^a   Aschauer, Stefan ^a   Bolger, Gordon ^d   Helson, Lawrence ^c   Wolzt, Michael ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b POLYMUN SCIENTIFIC IMMUNBIOLOGISCHE FORSCHUNG GMBH   (Austria)

^c SignPath Pharma Inc   (United States)

^d Nucro Technics ^*  (Canada)

Author keywords

Human; Liposomal curcumin; Pharmacokinetics; Red blood cells

Indexed keywords

ASPARTATE AMINOTRANSFERASE; CURCUMIN; DRUG METABOLITE; LACTIC ACID; LIPOSOMAL CURCUMIN; PLACEBO; TETRAHYDROCURCUMIN; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; DRUG URINE LEVEL; ECHINOCYTE; EPISTAXIS; ERYTHROCYTE VOLUME; FEMALE; GLUCOSURIA; HEADACHE; HUMAN; HUMAN EXPERIMENT; LACTATE BLOOD LEVEL; LIMB PAIN; LIMIT OF QUANTITATION; MALE; MAXIMUM PLASMA CONCENTRATION; NAUSEA; NORMAL HUMAN; OROPHARYNX PAIN; PHASE 1 CLINICAL TRIAL; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; RHINITIS; RHINOPHARYNGITIS; SHOCK; SIDE EFFECT; SINGLE DRUG DOSE; THORAX PAIN; TIME TO MAXIMUM PLASMA CONCENTRATION;

EID: 84964289669     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CP202076     Document Type: Article

References (27)

1. Aggarwal BB, Sundaram C, Malani N, Ichikawa H. Curcumin: the Indian solid gold. Adv Exp Med Biol. 2007; 595: 1-75. CrossRef PubMed
2. Goel A, Jhurani S, Aggarwal BB. Multi-targeted therapy by curcumin: how spicy is it? Mol Nutr Food Res. 2008; 52: 1010-1030. CrossRef PubMed
3. Ammon HP, Wahl MA. Pharmacology of Curcuma longa. Planta Med. 1991; 57: 1-7. CrossRef PubMed
4. Kuttan R, Bhanumathy P, Nirmala K, George MC. Potential anticancer activity of turmeric (Curcuma longa). Cancer Lett. 1985; 29: 197-202. CrossRef PubMed
5. Li L, Braiteh FS, Kurzrock R. Liposome-encapsulated curcumin: in vitro and in vivo effects on proliferation, apoptosis, signaling, and angiogenesis. Cancer. 2005; 104: 1322-1331. CrossRef PubMed
6. Li L, Ahmed B, Mehta K, Kurzrock R. Liposomal curcumin with and without oxaliplatin: effects on cell growth, apoptosis, and angiogenesis in colorectal cancer. Mol Cancer Ther. 2007; 6: 1276-1282. CrossRef PubMed
7. Helson L, Bolger G, Majeed M, Vcelar B, Pucaj K, Matabudul D. Infusion pharmacokinetics of Lipocurc™ (liposomal curcumin) and its metabolite tetrahydrocurcumin in Beagle dogs. Anticancer Res. 2012; 32: 4365-4370. PubMed
8. Wang YJ, Pan MH, Cheng AL, Lin LI, Ho YS, Hsieh CY, Lin JK. Stability of curcumin in buffer solutions and characterization of its degradation products. J Pharm Biomed Anal. 1997; 15: 1867-1876. CrossRef PubMed
9. Sharma RA, Steward WP, Gescher AJ. Pharmacokinetics and pharmacodynamics of curcumin. Adv Exp Med Biol. 2007; 595: 453-470. Cross- Ref PubMed
10. Sharma RA, Euden SA, Platton SL, Cooke DN, Shafayat A, Hewitt HR, Marczylo TH, Morgan B, Hemingway D, Plummer SM, Pirmohamed M, Gescher AJ, Steward WP. Phase I clinical trial of oral curcumin: biomarkers of systemic activity and compliance. Clin Cancer Res. 2004; 10: 6847-6854. CrossRef PubMed
11. Cheng AL, Hsu CH, Lin JK, Hsu MM, Ho YF, Shen TS, Ko JY, Lin JT, Lin BR, Ming-Shiang W, Yu HS, Jee SH, Chen GS, Chen TM, Chen CA, Lai MK, Pu YS, Pan MH, Wang YJ, Tsai CC, et al. Phase I clinical trial of curcumin, a chemopreventive agent, in patients with high-risk or pre-malignant lesions. Anticancer Res. 2001; 21 (4B): 2895-2900. PubMed
12. Vareed SK, Kakarala M, Ruffin MT, Crowell JA, Normolle DP, Djuric Z, Brenner DE. Pharmacokinetics of curcumin conjugate metabolites in healthy human subjects. Cancer Epidemiol Biomarkers Prev. 2008; 17: 1411-1417. CrossRef PubMed
13. report N-TV. Development and validation of an LC/MS/MS method for the measurement of Curcumin and Tetrahydrocurcumin (THC) in human plasma and its use in support of pharmacokinetic studies.2012. Report No.: NUCRO-TECHNICS PROJECT NO. 246975.
14. Aggarwal BB, Kumar A, Bharti AC. Anticancer potential of curcumin: preclinical and clinical studies. Anticancer Res. 2003; 23 (1A): 363-398. PubMed
15. Matabudul D, Pucaj K, Bolger G, Vcelar B, Majeed M, Helson L. Tissue distribution of (Lipocurc™) liposomal curcumin and tetrahydrocurcumin following two- and eight-hour infusions in Beagle dogs. Anticancer Res. 2012; 32: 4359-4364. PubMed
16. Baerlocher GM, Beer JH, Owen GR, Meiselman HJ, Reinhart WH. The anti-neoplastic drug 5-fluo rouracil produces echinocytosis and affects blood rheology. Br J Haematol. 1997; 99: 426-432. CrossRef PubMed
17. Reinhart WH, Baerlocher GM, Cerny T, Owen GR, Meiselman HJ, Beer JH. Ifosfamide-induced stomatocytosis and mesna-induced echinocytosis: influence on biorheological properties of blood. Eur J Haematol. 1999; 62: 223-230. CrossRef PubMed
18. Suwalsky M, Hernández P, Villena F, Aguilar F, Sotomayor CP. The anticancer drug adriamycin interacts with the human erythrocyte membrane. Z Naturforsch C. 1999; 54: 271-277. PubMed
19. Nelson GA, Andrews ML, Karnovsky MJ. Control of erythrocyte shape by calmodulin. J Cell Biol. 1983; 96: 730-735. CrossRef PubMed
20. Glaser R. Echinocyte formation induced by potential changes of human red blood cells. J Membr Biol. 1982; 66: 79-85. CrossRef PubMed
21. Sheetz MP, Singer SJ. Biological membranes as bilayer couples. A molecular mechanism of drugerythrocyte interactions. Proc Natl Acad Sci USA. 1974; 71: 4457-4461. CrossRef PubMed
22. Anderson RA, Lovrien RE. Erythrocyte membrane sidedness in lectin control of the Ca2+-A23187- mediated diskocyte goes to and comes from echinocyte conversion. Nature. 1981; 292: 158-161. CrossRef PubMed
23. Lovrien RE, Anderson RA. Stoichiometry of wheat germ agglutinin as a morphology controlling agent and as a morphology controlling agent and as a morphology protective agent for the human erythrocyte. J Cell Biol. 1980; 85: 534-548. CrossRef PubMed
24. Ferrell JE Jr, Huestis WH. Phosphoinositide metabolism and the morphology of human erythrocytes. J Cell Biol. 1984; 98: 1992-1998. CrossRef PubMed
25. Banerjee A, Kunwar A, Mishra B, Priyadarsini KI. Concentration dependent antioxidant/pro-oxidant activity of curcumin studies from AAPH induced hemolysis of RBCs. Chem Biol Interact. 2008; 174: 134-139. CrossRef PubMed
26. Storka A, Vcelar B, Klickovic U, Gouya G, Weisshaar S, Aschauer S, Helson L, Wolzt M. Effect of liposomal curcumin on red blood cells in vitro. Anticancer Res. 2013; 33: 3629-3634. PubMed
27. Cosimati R, Milardi GL, Bombelli C, Bonincontro A, Bordi F, Mancini G, Risuleo G. Interactions of DMPC and DMPC/gemini liposomes with the cell membrane investigated by electrorotation. Biochim Biophys Acta. 2013; 1828: 352-356. CrossRef PubMed